News und Analysen
Can Buying Exelixis Stock Still Make You Rich?
What were you doing on Friday, Jan. 2, 2015? It's OK if you don't remember. I certainly can't.But there were some investors who did something on that date who probably recall it with a smile.....
Why I Love AbbVie Inc.
"Where your treasure is, there will your heart be also."Those profound words were spoken nearly 2,000 years ago. They were true then, and they're still true today. But even when your treasure is....
These 3 Stocks Are Priced for Perfection. Can They Deliver?
Even great companies can turn into poor investments if you buy them at the wrong time. That's why it is important to take a hard look at a company's valuation before pulling the trigger.Shares of....
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Just because a big pharma company is successful today doesn't mean it will be successful in a few years. Even the biggest blockbuster drugs eventually lose patent exclusivity or face new and....
Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story....
3 States Where Obamacare Premiums May Rise More Than 50% in 2018
Despite President Trump having been in office for more than seven months now and Republicans retaining control of both houses of Congress, the Affordable Care Act, which is best known as....
Better Buy: Welltower Inc. vs. Universal Health Services, Inc.
America is getting older, and the demographic shift is driving up demand for healthcare facilities and services. This long-term trend should supply the nursing homes in Welltower Inc.'s (NYSE:....
3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
Illumina (NASDAQ: ILMN) has been -- and still is -- a leader in one of the most important scientific advances in human history. The company's technology helped usher in widespread use of gene....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
Major benchmarks trended downward Wednesday, taking a break from the rally that had boosted stocks in the previous session. Investors seemed uncertain about President Donald Trump's plans to....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
What's Next for Bristol-Myers Squibb After Its Opdivo Setback?
The signs were definitely there for a disappointment from Bristol-Myers Squibb (NYSE: BMY). Several weeks ago, AstraZeneca (NYSE: AZN) reported its checkpoint inhibitor Imfinzi failed to improve....
What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline?
Regeneron Pharmaceuticals (NASDAQ: REGN) has four significant medications on the market, including three that have won Food and Drug Administration approval since 2015, and it's investing big....
What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?
Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug....
Why Eylea Is Still Regeneron Pharmaceuticals' Most Important Drug
Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that's causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration....
3 Top Stocks Under $5
Tiny stocks don't get a lot of love on Wall Street -- and by tiny I mean companies that have a share price of under $5. According to the Securities and Exchange Commission, any stock that trades....
3 Most Promising Cancer Drugs in Late-Stage Development
Progress marches on in the fight against cancer. While more biosimilars are becoming available for top cancer drugs of the past, biopharmaceutical companies are developing newer and more powerful....
3 High-Yield Pharmaceutical Stocks
The pharmaceutical industry is a natural hunting ground for reliable income stocks, since people buy drugs in good times and in bad. But which high-yield dividend stocks are actually worthy of....
CVS Health Hopes Partnerships Will Power Growth
CVS Health Corp (NYSE: CVS) has had a rough go of it during the past year. Over the last twelve months, shares in the pharmaceutical drug store chain and pharmacy benefit manager (PBM) have dipped....
Here's Why Community Health Systems Surged Today
Shares of Community Health Systems (NYSE: CYH), a major operator of U.S. hospitals, jumped 12.8% on Monday before finishing the session about 8.7% higher. The ASL Strategic Value Fund sent a....
Better Buy: Veeva Systems Inc. vs. Cerner Corporation
Veeva Systems (NYSE: VEEV) and Cerner (NASDAQ: CERN) rank as two of the most successful healthcare technology companies of the past five years. Veeva's customer relationship management (CRM) and....
Better Buy: AbbVie Inc. vs. Pfizer Inc.
There's no question that AbbVie (NYSE: ABBV) shareholders have been happier campers than Pfizer (NYSE: PFE) shareholders in recent years. Whether you compare the two drug stocks over five years,....
Intuitive Surgical Stock Split: Everything You Need to Know
Robotic surgical pioneer Intuitive Surgical, Inc. (NASDAQ: ISRG) has had quite a run lately. So far this year, shares are up 56%, and over the past three years, the stock has more than doubled.....